Visit the Regional Educational Programs for more information about the following upcoming programming:

Industry-Supported Programs:

• July 17th - Understanding Acute Leukemia A Clinical Overview of AML and ALL, presented by Syndax Pharmaceuticals
• July 18th - KISQALI: A Brief Review of Reducing the Risk of Recurrence in HR+/HER2- Early Breast Cancer, presented by Novartis

https://asco.quorum.us/campaign/56411/

Enjoy this wonderful interview with 3 of NNECOS' founding members!

Latest FDA Approval

• June 23 - FDA grants accelerated approval to datopotamab deruxtecan-dlnk for EGFR-mutated non-small cell lung cancer
  June 18 - FDA approves tafasitamab-cxix for relapsed or refractory follicular lymphoma
• June 12 - FDA approves mitomycin intravesical solution for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
• June 12 - FDA approves neoadjuvant and adjuvant pembrolizumab for resectable locally advanced head and neck squamous cell carcinoma
• June 11 - FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
• June 3 - FDA approves darolutamide for metastatic castration-sensitive prostate cancer
• May 14 - FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression
• May 14 - FDA approves belzutifan for pheochromocytoma or paraganglioma
• May 8 - FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer
• April 24 - FDA approves penpulimab-kcqx for non-keratinizing nasopharyngeal carcinoma
• April 11 - FDA approves nivolumab with ipilimumab for unresectable or metastatic hepatocellular carcinoma
• April 8 - FDA approves nivolumab with ipilimumab for unresectable or metastatic MSI-H or dMMR colorectal cancer
• March 28 - FDA approves durvalumab for muscle invasive bladder cancer
• March 28 - FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication
• March 26 - FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET
• March 19 - FDA approves pembrolizumab for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1)

Package/Label Updates

Code Updates

• Claim Issue Reported 1/8/25 impacting Part B providers in Jurisdiction JK and Jurisdiction J6 - Claims with healthcare common procedure coding system (HCPCS) G2211 with date of service (DOS) 1/1/2024-9/30/2024.

• Effective for dates of service on or after April 1, 2024, the Centers for Medicare and Medicaid Services (CMS) has assigned the following Healthcare Common Procedure Coding System (HCPCS)* J-Code for ELREXFIO (elranatamab-bccm) injection:
  

Other Updates